�PolyMedix, Inc. (OTC BB: PYMX), an emerging ergonomics company developing new sanative drug products to treat infectious diseases and needlelike cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in Canada for its defensin mimetic antibiotic drug compound, PMX-30063. PolyMedix received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for PMX-30063 in May 2008. PMX-30063 is the first and only defensin mimetic antibiotic combine to come in human clinical trials for systemic habit, and represents an entirely new year of antibiotic drug drugs.
This first Phase I clinical trial will assess the safety of PMX-30063. The protocol for the test involves a dose-escalation study in healthy volunteers in which each subject testament receive a single venereal infection of PMX-30063. The subjects are sorted into different cohorts with different dose levels which will leave for the study of the personal effects of increased dosages. PolyMedix expects to enroll a total of thirty to fifty subjects in this clinical tryout. Upon successful completion of the first clinical report, PolyMedix plans to pioneer a secondment clinical tribulation to mimic the expected clinical dosing regimen. The second trial, also to be conducted in intelligent volunteers, will involve recapitulate dosing of two intravenous infusions per day, for up te verbal description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any innovative statements. PolyMedix undertakes no obligation to release publically the results of whatsoever revisions to any such forward-looking statements that whitethorn be made to meditate events or circumstances subsequently the date of this press handout or to reflect the occurrence of unanticipated events.
PolyMedix, Inc.
More information
